20/20 Biolabs (NASDAQ:AIDX) Releases Quarterly Earnings Results

20/20 Biolabs (NASDAQ:AIDX – Get Free Report) announced its earnings results on Monday. The company reported ($0.12) earnings per share for the quarter, Zacks reports.

20/20 Biolabs Stock Down 9.4%

Shares of NASDAQ AIDX traded down $0.02 during trading hours on Monday, reaching $0.18. 138,569 shares of the stock traded hands, compared to its average volume of 395,094. 20/20 Biolabs has a 52-week low of $0.18 and a 52-week high of $50.00. The company’s 50-day simple moving average is $0.35 and its two-hundred day simple moving average is $0.95. The company has a market capitalization of $2.47 million and a P/E ratio of -0.34.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of 20/20 Biolabs from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $5.00.

Check Out Our Latest Stock Report on AIDX

About 20/20 Biolabs

(Get Free Report)

20/20 BioLabs is a clinical laboratory company that has provided diagnostic testing services, with a focus on infectious diseases. Its offerings have included COVID-19 testing, such as molecular and antibody-based tests, along with related laboratory services. The company became known during the COVID-19 pandemic, when it supported demand for testing in the United States. Publicly available information about its broader operations and leadership is limited.

Read More

Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.